 August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals a measure of innovation in the biopharma sector numbered four for the month, taking the total for the year to 36, two less than relative to the same period in 2020. 